17-9-4-1　ⓔ文献

  1. Parker C, Omine M, et al: Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood, 2005; 106: 3699–3709.

  2. Brown KE, Tisdale J, et al: Hepatitis–associated aplastic anemia. N Engl J Med, 1997; 336: 1059–1064.

  3. 再生不良性貧血の診断基準と診療の参照ガイド改訂版作成のためのワーキンググループ：再生不良性貧血診療の参照ガイド　厚生労働科学研究費補助金難治性疾患克服研究事業特発性造血障害に関する調査研究班：特発性造血障害疾患の診療参照ガイド (令和元年度改訂版)，2020; 3–35.

  4. 太田晶子，島田直樹：再生不良性貧血の罹患率の推計―臨床調査個人票の解析．厚生労働科学研究費補助金難治性疾患克服研究事業　特発性造血障害に関する調査研究　平成28年度総括・分担研究報告書, 2017; 50–54.

  5. Nakao S, Takamatsu H, et al: Identification of a specific HLA class II haplotype strongly associated with susceptibility to cyclosporine–dependent aplastic anemia. Blood, 1994; 84: 4257–4261.

  6. Zaimoku Y, Takamatsu H, et al: Identification of an HLA class I allele closely involved in the autoantigen presentation in acquired aplastic anemia. Blood, 2017; 129: 2908–2916.

  7. Katagiri T, Sato–Otsubo A, et al: Frequent loss of HLA alleles associated with copy number–neutral 6pLOH in acquired aplastic anemia. Blood, 2011; 118: 6601–6609.

  8. Maruyama H, Katagiri T, et al: Clinical significance and origin of leukocytes that lack HLA–A allele expression in patients with acquired aplastic anemia. Exp Hematol, 2016; 44: 931–939 e933.

  9. Hosokawa K, Katagiri T, et al: Favorable outcome of patients who have 13q deletion: a suggestion for revision of the WHO 'MDS–U' designation. Haematologica, 2012; 97: 1845–1849.

  10. Sugimori C, Chuhjo T, et al: Minor population of CD55–CD59– blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood, 2006; 107: 1308–1314.

  11. Kulagin A, Lisukov I, et al: Prognostic value of paroxysmal nocturnal haemoglobinuria clone presence in aplastic anaemia patients treated with combined immunosuppression: results of two–centre prospective study. Br J Haematol, 2014; 164: 546–554.

  12. Yoshizato T, Dumitriu B, et al: Somatic mutations and clonal hematopoiesis in aplastic anemia. N Engl J Med, 2015; 373: 35–47.

  13. Seiki Y, Sasaki Y, et al: Increased plasma thrombopoietin levels in patients with myelodysplastic syndrome: a reliable marker for a benign subset of bone marrow failure. Haematologica, 2013; 98: 901–907.

  14. Nakao S, Gale RP: Are mild/moderate acquired idiopathic aplastic anaemia and low–risk myelodysplastic syndrome one or two diseases or both and how should it/they be treated? Leukemia, 2016; 30: 2127–2130.

  15. Winkler T, Fan X, et al: Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag. Blood, 2019; 133: 2575–2585.

  16. Saito C, Ishiyama K, et al: Hypomegakaryocytic thrombocytopenia (HMT): an immune–mediated bone marrow failure characterized by an increased number of PNH–phenotype cells and high plasma thrombopoietin levels. Br J Haematol, 2016; 175: 246–251.

  17. Townsley DM, Scheinberg P, et al: Eltrombopag added to atandard immunosuppression for aplastic anemia. N Engl J Med, 2017; 376: 1540–1550.